Effects of Glucagon-Like Peptide-1 Receptor Activators in Multiple Sclerosis: A Focused Review

GLP-1 receptor agonists may be prescribed for various comorbidities in patients with multiple sclerosis.

• GLP-1 receptor agonists are approved for managing obesity and improving glycemic control in type 2 diabetes.
• Patients with multiple sclerosis often have comorbidities like obesity, diabetes, and chronic kidney disease that GLP-1 receptor agonists may address.
• The review discusses the safety and tolerability of GLP-1 receptor agonists for weight loss in patients with multiple sclerosis.
• Efficacy of GLP-1 receptor agonists for non-MS approved indications is considered for patients with multiple sclerosis.
• Potential effects of GLP-1 receptor agonists on the progression of multiple sclerosis beyond their approved uses are explored.

Simplified